Sara Trompeter, MD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the implementation of the Sickle Cell and Thalassemia Blood Group Genotyping Program into healthcare systems. Sponsored by NHS England, this program encourages patients with sickle cell disease (SCD), thalassemia, and rare inherited anemia to participate, in order to enhance donor compatibility for improved transfusion outcomes. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.